BMO Capital analyst Evan Seigerman keeps an Outperform rating and $385 price target on Vertex Pharmaceuticals after the company disclosed updated data for six T1D patients treated with VX-880 in Part A/B of Phase 1/2 trial that showed treatment benefit, including endogenous insulin secretion, improved glycemic control, and endogenous insulin reduction/elimination. The data could allow investors to get comfortable with Vertex’s T1D program, although BMO prefers more clarity on path to commercialization given nuance of T1D cell therapy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals and Lonza to build facility for T1D cell therapies
- Vertex Pharmaceuticals reports ‘positive’ Phase 1/2 VX-880 results
- Vertex announces FDA approval for KALYDECO to treat eligible infants with CF
- Vertex Pharmaceuticals price target raised to $400 from $325 at Maxim
- Vertex Pharmaceuticals price target raised to $363 from $344 at Bernstein